HomeHealthcare & Life SciencesPharmaceuticals Myasthenia Gravis Treatment Market

Singapore Myasthenia Gravis Treatment Market Size & Outlook, 2025-2033


Singapore Myasthenia Gravis Treatment Market Insights

  • According to Reed Intelligence analysis, the Singapore Myasthenia Gravis Treatment Market size was USD 8.56 Million in 2024 and is projected to reach USD 21.03 Million by 2033.
  • The Singapore market is projected to grow at a CAGR of 10.53% between 2026 and 2033.
  • By segment, Ocular MG  emerged as the largest By Type in terms of market size in 2024.
  • Transient Neonatal MG is anticipated to remain the most attractive By Type segment, recording the fastest growth during the forecast period.

Other Key Findings


  • Singapore accounted for 0.41% of the global Myasthenia Gravis Treatment Market size in 2024.
  • By 2033, United States is expected to remain the top global market in terms of size.
  • Within Asia Pacific, China is forecasted to dominate the regional Myasthenia Gravis Treatment Market size by 2033.
  • South East Asia will be the fastest-growing market in Asia Pacific, projected to achieve USD 84.74 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 8.56 Million
Market Size In 2033 USD 21.03 Million
Largest segment Ocular MG 
Units Revenue in USD Million
CAGR 10.53% (2025-2033)
Segmnetation Covered
By Type
  1. Ocular MG 
  2. Congenital MG 
  3. Transient Neonatal MG
By Treatment
  1. Medication 
  2. Surgery 
  3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
  4. Plasmapheresis and Intravenous Immunoglobulin 
  5. Others
By End-User
  1. Hospitals 
  2. Clinics 
  3. Academic Research Institutes 
  4. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports